Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
Date:3/5/2012

SAN DIEGO, March 5, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2011 financial results on Monday, March 12, 2012.

Cadence management will host a conference call and live webcast to discuss the financial results on Monday, March 12, 2012 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international).  To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page.  A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  For more information about Cadence, please visit www.cadencepharm.com.

 Contacts:

William R. LaRue 

SVP & Chief Financial Officer 

Cadence Pharmaceuticals, Inc. 

858-436-1400


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2011 Financial Results on August 3, 2011
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
4. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
5. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
7. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
8. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
9. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Australian prostate ... a prestigious Australian science prize recognising ,outstanding, science that ... track to globally launch a novel prostate cancer diagnostic ... a high level consortium taking out the peer-reviewed Australian ... Scientific Research. This prize is awarded ...
(Date:9/2/2015)... Colo. , Sept. 2, 2015 Aytu ... on developing treatments for urological and related conditions, announced ... its planned private placement convertible note financing, raising a ... prior tranches totaling $3.175 million. ... "Proceeds from this private placement are intended to be ...
(Date:9/2/2015)... FRANCISCO, Calif. , Sept. 2, 2015 ... Bonnie H. Anderson , president and chief executive ... Conference on Wednesday, September 16, 2015 at 10:30 a.m. ... The live audio webcast and subsequent ... . The webcast will be available shortly after conclusion ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
Breaking Biology Technology:Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... Calif., Nov. 5 Onyx,Pharmaceuticals, Inc. (Nasdaq: ... the 2008 Credit Suisse Health Care Conference on ... a.m. Pacific Time). Interested parties,may access a live ... http://www.onyx-pharm.com/wt/page/event_calendar , It is recommended that listeners ...
... ... - - Quantitative HER2 Scores Now Included in All Oncotype DX Reports - ... - Conference Call Today at 4:30 p.m. ET -, REDWOOD CITY, Calif., Nov. ... progress,for the quarter ended September 30, 2008., Total revenue increased to $28.1 million ...
... /PRNewswire-FirstCall/ - Dr. Brad Thompson, President,and CEO of Oncolytics ... and webcast on Thursday, November 6, 2008 at,11:00 a.m. ... trial results,in its U.S. Phase II trial for patients ... The results are scheduled to be presented November,6, 2008 ...
Cached Biology Technology:Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 2Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 3Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 4Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 5Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 6Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 7Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 8Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call 2
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... bird in hand is worth two in the bush may ... the lab of ASU School of Life Sciences Professor Roy ... at the Biodesign Institute. There, associate research scientist ... targets to develop a vaccine against a leading poultry disease, ...
... working gene is inserted into a cell to replace a ... the prevention and treatment of disease. Now a ... a counterintuitive approach also holds promise. The targeted removal of ... would do -- can restore cellular function in cells with ...
... United Kingdom and France have identified four separate ... Creutzfeldt-Jakob disease. The study, published March 14th in ... subgroups could represent distinct prion strains in what ... Prion diseases are transmissible neurodegenerative disorders characterized by ...
Cached Biology News:Solving an avian scourge could also provide benefits to human health 2Solving an avian scourge could also provide benefits to human health 3Work with power grids leads to cell biology discovery 2Work with power grids leads to cell biology discovery 3
... Synthetic peptide derived from the C-terminal region ... kinase C zeta isoform (PKCzeta). Specificity: ... protein. Recognizes PKCzeta and PKMzeta (PKCzeta ... Reactivity: Mouse Rat (positive controls: mouse ...
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
...
Biology Products: